Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG vs basiliximab induction in liver transplantation after preoperative PD-1 inhibitors for hepatocellular carcinoma
ChiCTR2600122712Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in hepatocellular carcinoma (HCC) comparing Control group - basiliximab induction with Research group - ATG induction (2 arms). Primary endpoint: Incidence rate of acute rejection. Started Apr 2026; status: recruiting.
02
Drugs
antithymocyte globulin rabbitbasiliximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600122712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122712.